HALAVEN
EISSAI EUROPE
Identification
- Active ingredient (INN)
- ERIBULINE MESILATE EXPERIME EN ERIBULINE
- Internal code
- 05 G 191
- Country of Origin
- United Kingdom
- Pharmaceutical form
- IV Injectable Solution
- Prescription List
- Highly Regulated (List I)
- Packaging
- b/1 flacon de 2 ml
DAWA Clinical Workbench v2.0
Information may not be accurate. Always consult a physician, pharmacist, or specialist before acting on any data shown here.
Indications
It is used to treat the cancer of the sick who received at least two former treatment systems containing anthraciclane.
Associated Conditions
The use of this drug may cause blood toxicity, including a reduction in the progeny, and the fever that accompany it, which may require a stop or a reduction in the dose.
High levels of liver enzymes and belrubin are more likely to be infected with blood toxicity when using ebola.
Mechanism of Action
It simulates the coat of coats, stopping the process of equitable division, stopping the cell's life cycle in the second stage of development, and cellular division, and thus leading to the death of reproductive cells in cancer.
Do you have questions on this subject? Ask Sina, artificial intelligence to answer all your medical questions, write your question here, Sina, prepare the answer for you.